Last checked at 15 Nov 2017 16:37
ValiRx Plc
("ValiRx" or "the Company" or "the Group")
Loan Note Conversion and Issue of Equity
London, UK., 15 November 2017: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering, announces the partial conversion of the first and second tranches, and the repayment of the third tranche, of the YA II CD, Ltd. ("YA II") Convertible Loan Facility ("CLN"), the terms of which are described in the announcement dated 2 September 2016.
YA II has elected to convert US$40,105.06 of its CLN (plus accrued interest of US$919.67) from Tranche 1 and US$10,000.00 of its CLN (plus accrued interest of US$101,892.42) from Tranche 2 into 12,446,476 ordinary shares at a conversion price of 0.9271p per share.
Tranche one has therefore now been converted in full.
US$1,216,203 (plus accrued interest) of tranche 2 of the CLN remains outstanding.
The Company has elected to repay US$400,000 (being the total amount drawn down to date) from tranche 3 in cash and not to make any further drawdowns.
Application for the 12,446,476 ordinary shares will be made to the London Stock Exchange and trading in these shares is expected to commence on or around 20 November 2017.
Following the issue of equity above the Company's issued share capital will comprise of 216,405,413.
The Table below sets out a summary (excluding accrued interest) of the facility following the conversions and repayment detailed above:-
Tranche 1 | Tranche 2 | Tranche 3 | Total | |
Par value of tranche | US$1,250,000 | US$1,250,000 | US$1,250,000 | US$2,900,000 |
Amount drawn down | (US$1,250,000) | (US$1,250,000) | US$400,000 | (US$2,900,000) |
Balance of tranche available for drawdown | nil | nil | nil* | nil |
Total conversion / repayment of tranche into ordinary shares/ for cash | US$1,250,00 | US$33,797 | US$400,000 | US$1,683,797 |
Balance of tranche outstanding | nil | US$1,216,203 | nil* | US$1,216,202 |
*No further balance available as the Company has elected to close tranche 3 of the facility.
Each tranche has a maturity date of 12 months from the date of drawdown. The Convertible Loan Notes bear an interest rate of 9 per cent. per annum.
This announcement is inside information for the purposes of Article 7 of Regulation 596/2014.
*** ENDS ***
For more information, please contact:
ValiRx plc | Tel: +44 (0) 20 3008 4416 www.valirx.com |
Dr Satu Vainikka, Chief Executive | Tel: +44 (0) 20 3008 4416 |
Tarquin Edwards, Head of Communications. | Tel: +44 (0) 7879 458 364 tarquin.edwards@valirx.com |
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/Jo Turner/Richard Nash | Tel: +44 (0) 20 7213 0880 |
Beaufort Securities Limited (Broker) Jon Belliss | Tel: +44 (0) 207 382 8300 |
Notes for Editors
About ValiRx
ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.
ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.
The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.